Navigation Links
Cadence Pharmaceuticals Reports Third Quarter 2013 Financial Results
Date:11/5/2013

ctivities; public concern regarding the safety of drug products such as OFIRMEV, and the potential implementation by regulatory agencies of new requirements to include unfavorable information in the labeling for OFIRMEV; the risk that Cadence may not be able to raise sufficient capital when needed, or at all; and other risks detailed under "Risk Factors" and elsewhere in Cadence's periodic reports and other filings made with the Securities and Exchange Commission from time to time. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995, and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Cadence® and OFIRMEV® are trademarks of Cadence Pharmaceuticals, Inc.

Contact:

William R. LaRueSVP & Chief Financial OfficerCadence Pharmaceuticals, Inc.Phone: 858-436-1400 

 CADENCE PHARMACEUTICALS, INC.CONDENSED STATEMENTS OF OPERATIONS(unaudited)(in thousands, except per share amounts)Three Months EndedNine Months EndedSeptember 30,September 30,2013201220132012Revenues:Product revenue, net

$
28,957$
3,898$
77,243$
32,977License revenue

---33Total revenues

28,95713,89877,24333,010Costs and expenses:Cost of product sales

9,9646,07626,42516,078Amortization of patent license

3363361,0081,008Research and development

1,6552,2354,6985,446Selling, general and administrative

22,92820,03970,26166,811Other

(107)13(602)14Total costs and expenses

34,77628,699101,79089,357Loss from operations

(5,819)(14,801)(24,547)(56,347)Other (expense) income, net

(1,119)(1,089)4,371(3,205)Net loss

$
(6,938)$
(15,890)$
(20,176)$
(59,552)Basic and diluted net loss pe
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Third Quarter 2013 Financial Results On November 5, 2013
2. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2013 On September 11, 2013
3. Cadence Pharmaceuticals Comments on USPTOs Non-Final, Initial Office Action on Reexamination of Patent
4. Cadence Pharmaceuticals Appoints Laureen DeBuono to its Board of Directors
5. Cadence Pharmaceuticals To Present At The 2013 Wedbush PacGrow Life Sciences Management Access Conference On August 13, 2013
6. Cadence Pharmaceuticals Reports Second Quarter 2013 Financial Results
7. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Second Quarter 2013 Financial Results On July 31, 2013
8. Cadence Pharmaceuticals To Present At Three Investment Conferences During The Month Of May 2013
9. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss First Quarter 2013 Financial Results On May 2, 2013
10. Cadence Pharmaceuticals Appoints Stephen L. Newman, M.D., to its Board of Directors
11. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Australian drug delivery ... that it has raised A$19.3 million via a placement ... Europe , the U.S., Asia ... million from a share purchase plan (SPP) to be ... will be made in two tranches. "This ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
(Date:7/10/2014)... NEWS, Virginia , 11. Juli ... Hersteller von Kameras für die molekulare ... (MBI/BSGI), hat heute die CE-Zulassung für ... dem CE-Zeichen kann Dilon das Produkt ... Vertriebsbereich auf den Großteil der europäischen ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Veran Medical Publishes Lung Cancer Patient Management Study 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2
... , Part of International Internet Week ... The U.S. Food and Drug Administration today completed ... Week of Action (IIWA), intended to curb illegal actions ... During the effort, the FDA,s Office of Criminal Investigations ...
... , Primary Care Doctors, Endocrinologists Feel ... N.J., Nov. 19 Nearly one-third of doctors surveyed said ... sufficient reimbursement to provide comprehensive care to their patients with ... and primary care doctors published today in American Health ...
Cached Medicine Technology:UPDATE: FDA Issues 22 Warning Letters to Web site Operators 2Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 2Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 3Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 4Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show 5
(Date:7/11/2014)... The report “Probiotics Market by ... Feed), Applications (Regular, Therapeutic, Preventive Health Care) & ... Forecasts to 2019 ” defines and segments the ... of the market value of probiotic products and ... restraining factors for the global market with an ...
(Date:7/11/2014)... Global enterprises today are shifting towards the changing trend ... services offer these global enterprises a strategic method to ... rising operational costs to companies. The aim to minimize ... global market driver for expanding the managed services market ... is estimated to grow from $142.75 billion in 2013 ...
(Date:7/11/2014)... Toledo, Ohio (PRWEB) July 11, 2014 ... (Morgenson 7/10/14) and FiercePharma (Weintraub 7/11/14), a significant number ... in blood sugar, abdominal issues and even death from ... exposed. , According to the Times report , ... events in 2013 reported by patients was almost 14% ...
(Date:7/11/2014)... its kind has found that organic foods and ... conventional counterparts, including more antioxidants and fewer, less ... an unprecedented 343 peer-reviewed publications comparing the nutritional ... foods, including fruits, vegetables, and grains. The study ... between organic and non-organic foods. , "Science ...
(Date:7/11/2014)... HealthDay Reporter THURSDAY, July 10, 2014 ... the worldwide scourge of dengue fever was somewhat successful in ... prevented dengue fever in 56 percent of the 10,000 kids ... more than 88 percent of them from severe disease. In ... sometimes death. "This vaccine has already proven to be ...
Breaking Medicine News(10 mins):Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3
... 1 (HealthDay News) -- Increasing daily soluble fiber intake may ... other substances linked to a host of chronic diseases, according ... found just under the skin, visceral fat is located deep ... Researchers at Wake Forest Baptist Medical Center found the way ...
... believe medical practitioners can help reduce the number of ... effectively educating their patients about the importance of mammography ... the Journal of Cancer Education , Rosalie Young, ... and Jason Booza, Ph. D., assistant professor, all from ...
... Researchers from the University of Leeds will carry out a ... or treat the spread of bowel cancer to the liver. ... of pure Eicosapentaenoic Acid (EPA) - a naturally occurring omega-3 ... oil preparations in health stores and supermarkets nationwide. Gastroenterologist ...
... (MGH) researchers have discovered the first of an entirely ... with the development of blood vessels. In a report ... /Early Edition, the investigators describe how a compound derived ... novel mechanism, to interfere with blood vessel formation in ...
... The Obama administration turned a bright spotlight on prescription ... Drug Control Policy released a national action plan and ... cover article in the July edition of the ... focus that spotlight on themselves both as major sources ...
... Bill Keevil, Head of the Microbiology Group and ... University of Southampton, has presented research into the ... on antibiotic-resistant organisms at the World Health Organization,s ... (ICPIC). ,New Insights into the Antimicrobial Mechanisms ...
Cached Medicine News:Health News:Soluble Fiber Appears Key to Trimming 'Bad Fat' 2Health News:Health providers should emphasize breast cancer screening, Wayne State University research finds 2Health News:Leeds researchers test benefit of fish oil in bowel cancer spread 2Health News:Mass. General team identifies new class of antiangiogenesis drugs 2Health News:Research examines dentists' role in painkiller abuse 2Health News:Research examines dentists' role in painkiller abuse 3Health News:Copper reduces infection risk by more than 40 percent 2
...
... accommodate a variety of applications across a ... DestinyPlus is suitable for any laboratory demanding ... a mixed-mode throughput exceeding 95 PT/aPTT/Fibrinogen per ... full range of chromogenics, the AMAX DestinyPlus ...
Non-invasive and continuous tcpCO2 and tcpO2 patient monitoring....
Two separate sensors provide continuous measurement of tcpO2/tcpCO2 and SpO2....
Medicine Products: